RT Journal Article
SR Electronic
T1 Detection of pneumococcus during hospitalization for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.13.22277607
DO 10.1101/2022.07.13.22277607
A1 Watkins, Anne E.
A1 Glick, Laura R.
A1 Ott, Isabel M.
A1 Craft, Samuel B.
A1 Yolda-Carr, Devyn
A1 Harden, Christina A.
A1 Nakahata, Maura
A1 Farhadian, Shelli F.
A1 Grant, Lindsay R.
A1 Alexander-Parrish, Ronika
A1 Arguedas, Adriano
A1 Gessner, Bradford D.
A1 Weinberger, Daniel M.
A1 Wyllie, Anne L.
YR 2022
UL http://medrxiv.org/content/early/2022/07/15/2022.07.13.22277607.abstract
AB Background Infections with respiratory viruses (e.g., influenza, RSV) can increase the risk of severe pneumococcal infections. Likewise, pneumococcal co-infection is associated with poorer outcomes in viral respiratory infection. However, there are limited data describing the frequency of pneumococcus and SARS-CoV-2 co-infection and the role of co-infection in influencing COVID-19 severity.Methods The study included patients admitted to Yale-New Haven Hospital who were symptomatic for respiratory infection and tested positive for SARS-CoV-2 during March-August 2020. Patients were tested for pneumococcus through culture-enrichment of saliva followed by RT-qPCR (to identify carriage) and serotype-specific urine antigen detection (UAD) assays (to identify presumed lower respiratory tract pneumococcal disease).Results Among 148 subjects, the median age was 65 years; 54.7% were male; 50.7% had an ICU stay; 64.9% received antibiotics; 14.9% died while admitted. Pneumococcal carriage was detected in 3/96 (3.1%) individuals tested by saliva RT-qPCR. Additionally, pneumococcus was detected in 14/127 (11.0%) individuals tested by UAD, and more commonly in severe than moderate COVID-19 (OR: 2.20; 95% CI: [0.72, 7.48]); however, the numbers were small with a high degree of uncertainty. None of the UAD-positive individuals died.Conclusions Pneumococcal LRTI, as detected by positive UAD, occurred in patients hospitalized with COVID-19. Moreover, pneumococcal LRTI was more common in those with more serious COVID-19 outcomes. Future studies should assess how pneumococcus and SARS-CoV-2 interact to influence COVID-19 severity in hospitalized patients.One Sentence Summary Pneumococcal lower respiratory tract infection, as detected by positive UAD, occurred in patients hospitalized with COVID-19 at rates similar to those reported prepandemic.Competing Interest StatementALW has received consulting and/or advisory board fees from Pfizer, RADx, Diasorin, PPS Health, Co-Diagnostics, Filtration Group, and Global Diagnostic Systems for work unrelated to this project, and is Principal Investigator on research grants with Pfizer, Merck, Flambeau Diagnostics, Tempus Labs, and The Rockefeller Foundation to Yale University. DMW has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this project and is Principal Investigator on research grants and contracts with Pfizer and Merck to Yale University.Funding StatementThis study was performed as a collaborative research project between researchers at Yale School of Public Health and Pfizer. The study protocol was designed by the Yale researchers in consultation with Pfizer. The decision to publish was made by the Yale researchers in consultation with Pfizer; all authors agree with the decision to publish and with the results of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Signed informed consent was obtained from all study participants following Yale University HIC-approved protocol #2000027690.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.